Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.

[1]  F. Krammer,et al.  Monoclonal Antibodies with Neutralizing Activity and Fc-Effector Functions against the Machupo Virus Glycoprotein , 2019, Journal of Virology.

[2]  Alessandro Arcovito,et al.  Cryo-EM structure of the human ferritin–transferrin receptor 1 complex , 2019, Nature Communications.

[3]  S. Cordo,et al.  Assessing cross‐reactivity of Junín virus‐directed neutralizing antibodies , 2019, Antiviral research.

[4]  I. Lukashevich,et al.  Attenuated Replication of Lassa Virus Vaccine Candidate ML29 in STAT-1-/- Mice , 2019, Pathogens.

[5]  P. Jahrling,et al.  Non-neutralizing antibodies elicited by recombinant Lassa–Rabies vaccine are critical for protection against Lassa fever , 2018, Nature Communications.

[6]  A. Sinchi.  Epidemiology and virology of New World Arenaviruses , 2018, International Journal of Infectious Diseases.

[7]  C. Peyrefitte,et al.  Description and characterization of a novel live-attenuated tri-segmented Machupo virus in Guinea pigs , 2018, Virology Journal.

[8]  M. Friedrich.  WHO's Blueprint List of Priority Diseases. , 2018, JAMA.

[9]  K. Wucherpfennig,et al.  Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses , 2018, Nature Communications.

[10]  I. Lukashevich,et al.  Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins , 2017, Vaccine.

[11]  I. Lukashevich,et al.  Diagnostics for Lassa Fever: Detecting Host Antibody Responses. , 2018, Methods in molecular biology.

[12]  G. Palacios,et al.  An attenuated Machupo virus with a disrupted L-segment intergenic region protects guinea pigs against lethal Guanarito virus infection , 2017, Scientific Reports.

[13]  K. Harlos,et al.  Convergent immunological solutions to Argentine hemorrhagic fever virus neutralization , 2017, Proceedings of the National Academy of Sciences.

[14]  J. C. de la Torre,et al.  Absence of an N-Linked Glycosylation Motif in the Glycoprotein of the Live-Attenuated Argentine Hemorrhagic Fever Vaccine, Candid #1, Results in Its Improper Processing, and Reduced Surface Expression , 2017, Front. Cell. Infect. Microbiol..

[15]  W. Maury,et al.  Differences in Glycoprotein Complex Receptor Binding Site Accessibility Prompt Poor Cross-Reactivity of Neutralizing Antibodies between Closely Related Arenaviruses , 2017, Journal of Virology.

[16]  A. Kuehne,et al.  Monoclonal antibody therapy for Junin virus infection , 2016, Proceedings of the National Academy of Sciences.

[17]  P. Maes,et al.  Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever , 2016, Journal of Virology.

[18]  J. Shamblin,et al.  Pathogenesis of Bolivian Hemorrhagic Fever in Guinea Pigs , 2016, Veterinary pathology.

[19]  S. Harrison,et al.  Molecular Basis for Antibody-Mediated Neutralization of New World Hemorrhagic Fever Mammarenaviruses. , 2015, Cell host & microbe.

[20]  S. Hallam,et al.  Machupo Virus Expressing GPC of the Candid#1 Vaccine Strain of Junin Virus Is Highly Attenuated and Immunogenic , 2015, Journal of Virology.

[21]  A. Griffiths,et al.  Genetic Changes at the Glycoprotein Editing Site Associated With Serial Passage of Sudan Virus. , 2015, The Journal of infectious diseases.

[22]  Eric M. Mucker,et al.  Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses , 2015, BioMed research international.

[23]  Jens H. Kuhn,et al.  Past, present, and future of arenavirus taxonomy , 2015, Archives of Virology.

[24]  J. C. de la Torre,et al.  The Glycoprotein Precursor Gene of Junin Virus Determines the Virulence of the Romero Strain and the Attenuation of the Candid #1 Strain in a Representative Animal Model of Argentine Hemorrhagic Fever , 2015, Journal of Virology.

[25]  T. Koma,et al.  A Substitution in the Transmembrane Region of the Glycoprotein Leads to an Unstable Attenuation of Machupo Virus , 2014, Journal of Virology.

[26]  S. Paessler,et al.  Epidemiology and pathogenesis of Bolivian hemorrhagic fever. , 2014, Current opinion in virology.

[27]  P. Pushko,et al.  Alphavirus Replicon Vectors for Prophylactic Applications and Cancer Intervention , 2014 .

[28]  Jan C. Varada,et al.  A neutralization assay for respiratory syncytial virus using a quantitative PCR-based endpoint assessment , 2013, Virology Journal.

[29]  K. Peden,et al.  Development of a Neutralization Assay for Influenza Virus Using an Endpoint Assessment Based on Quantitative Reverse-Transcription PCR , 2013, PloS one.

[30]  I. Lukashevich,et al.  Vaccine Platforms to Control Arenaviral Hemorrhagic Fevers. , 2012, Journal of vaccines & vaccination.

[31]  I. Lukashevich,et al.  Evaluation of Lassa virus vaccine immunogenicity in a CBA/J-ML29 mouse model. , 2012, Vaccine.

[32]  S. Nichol,et al.  The Major Determinant of Attenuation in Mice of the Candid1 Vaccine for Argentine Hemorrhagic Fever Is Located in the G2 Glycoprotein Transmembrane Domain , 2011, Journal of Virology.

[33]  J. Kuhn,et al.  Machupo Virus Glycoprotein Determinants for Human Transferrin Receptor 1 Binding and Cell Entry , 2011, PloS one.

[34]  G. Gamboa,et al.  Argentine hemorrhagic fever vaccines , 2011, Human vaccines.

[35]  Christopher J. Miller,et al.  Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques. , 2011, Vaccine.

[36]  J. C. de la Torre,et al.  Rescue from Cloned cDNAs and In Vivo Characterization of Recombinant Pathogenic Romero and Live-Attenuated Candid #1 Strains of Junin Virus, the Causative Agent of Argentine Hemorrhagic Fever Disease , 2010, Journal of Virology.

[37]  P. Snoy.  Establishing Efficacy of Human Products Using Animals , 2010, Veterinary pathology.

[38]  S. Paessler,et al.  TC83 replicon vectored vaccine provides protection against Junin virus in guinea pigs. , 2010, Vaccine.

[39]  S. Harrison,et al.  Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses , 2010, Nature Structural &Molecular Biology.

[40]  J. Iserte,et al.  Molecular analysis of the virulence attenuation process in Junín virus vaccine genealogy , 2010, Virus Genes.

[41]  J. Greenbaum,et al.  A Multivalent and Cross-Protective Vaccine Strategy against Arenaviruses Associated with Human Disease , 2009, PLoS pathogens.

[42]  V. Bondarev,et al.  [Chemotherapy for Bolivian hemorrhagic fever in experimentally infected guinea pigs]. , 2009, Voprosy virusologii.

[43]  R. Tesh,et al.  Reemergence of Bolivian Hemorrhagic Fever, 2007–2008 , 2009, Emerging infectious diseases.

[44]  D. Stuart,et al.  Unusual Molecular Architecture of the Machupo Virus Attachment Glycoprotein , 2009, Journal of Virology.

[45]  D. Enria,et al.  Junin (Argentine Hemorrhagic Fever) , 2009 .

[46]  N. Dziuba,et al.  Pathogenesis of XJ and Romero strains of Junin virus in two strains of guinea pigs. , 2008, The American journal of tropical medicine and hygiene.

[47]  Jens H. Kuhn,et al.  Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses , 2007, Nature.

[48]  D. Enria,et al.  Junin virus vaccines. , 2002, Current topics in microbiology and immunology.

[49]  P. Jahrling,et al.  Individual and Bivalent Vaccines Based on Alphavirus Replicons Protect Guinea Pigs against Infection with Lassa and Ebola Viruses , 2001, Journal of Virology.

[50]  V. Romanowski,et al.  Molecular characterization of attenuated Junin virus strains. , 1997, The Journal of general virology.

[51]  C. Peters,et al.  Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. , 1996, Vaccine.

[52]  Re-emergence of Bolivian hemorrhagic fever. , 1994, Epidemiological bulletin.

[53]  A. Kuehne,et al.  Safety and immunogenicity of a live-attenuated Junin (Argentine hemorrhagic fever) vaccine in rhesus macaques. , 1993, The American journal of tropical medicine and hygiene.

[54]  J. McCormick,et al.  Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. , 1989, The Journal of general virology.

[55]  P. Jahrling,et al.  Experimental studies of arenaviral hemorrhagic fevers. , 1987, Current topics in microbiology and immunology.

[56]  J. Maiztegui,et al.  IMPORTANCE OF DOSE OF NEUTRALISING ANTIBODIES IN TREATMENT OF ARGENTINE HAEMORRHAGIC FEVER WITH IMMUNE PLASMA , 1984, The Lancet.

[57]  J. Maiztegui,et al.  EFFICACY OF IMMUNE PLASMA IN TREATMENT OF ARGENTINE HÆMORRHAGIC FEVER AND ASSOCIATION BETWEEN TREATMENT AND A LATE NEUROLOGICAL SYNDROME , 1979, The Lancet.

[58]  G. Eddy,et al.  Protection of monkeys against Machupo virus by the passive administration of Bolivian haemorrhagic fever immunoglobulin (human origin). , 1975, Bulletin of the World Health Organization.

[59]  J. Maiztegui,et al.  [Argentine hemorrhagic fever]. , 1978, Medicina.

[60]  K. Johnson,et al.  Isolation of Machupo virus from wild rodent Calomys callosus. , 1966, American Journal of Tropical Medicine and Hygiene.

[61]  R. Mackenzie,et al.  EPIDEMIC HEMORRHAGIC FEVER IN BOLIVIA. I. A PRELIMINARY REPORT OF THE EPIDEMIOLOGIC AND CLINICAL FINDINGS IN A NEW EPIDEMIC AREA IN SOUTH AMERICA. , 1964, The American journal of tropical medicine and hygiene.